Cytiva Completes Renovation on Fast Trak cGMP Facility
The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000L.
Cytiva announced on June 24, 2020 that it has completed a renovation of its Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, MA.
The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000, according to a company press release. The site offers technical support and single-use biomanufacturing expertise to biotechnology companies looking for assistance in bringing therapeutics to market.
“Biotechnology companies are increasingly outsourcing their manufacturing, whether to access expertise, capacity, or both,” said Olivier Loeillot, senior vice-president, BioProcess at Cytiva, in the press release. “Our upgraded Fast Trak cGMP facility will provide our customers, particularly the small to mid-size companies, with the services and expertise needed to help expedite their processes and get to market faster.”
Source: Cytiva
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
